Cambridge Healthtech Institute’s 2nd Annual
Biologics for Autoimmune Diseases
New Science and Technology to Empower the Next Wave of Autoimmunity Therapeutics
May 11-12, 2026
Autoimmune disorders present enormous diversity in pathology and patient response, demanding equally diverse therapeutic approaches. Cambridge Healthtech Institute's 2nd annual Biologics for Autoimmune Diseases conference will showcase how next-generation biologics are being designed to meet that challenge across musculoskeletal, skin, gut, and systemic indications. Sessions will cover engineered Treg and T cell therapies, novel antibody and multispecific formats, and innovative delivery strategies for diseases like rheumatoid arthritis, psoriasis, Crohn’s disease, and rare autoimmune syndromes. Attendees will also see how AI-driven design, translational models, and multiomics integration are shaping drug discovery and patient stratification. By drawing on lessons from oncology, this track highlights emerging modalities, safety engineering, and mechanism-focused innovations that are redefining immune tolerance and reshaping treatment possibilities for autoimmune diseases.
Coverage will include, but is not limited to:
Targeting the Musculoskeletal System
- Engineered Treg and T cell therapies for immune tolerance
- Emerging engineered modalities
- Leveraging multimodal therapies to address complex inflammatory pathways and heterogeneous patient responses
- Novel strategies for RA, ankylosing spondylitis, and psoriatic arthritis
- Sustained release and local delivery strategies
Targeting Skin
- Advances in treating psoriasis, atopic dermatitis, and hidradenitis suppurativa therapies
- Cell-based and tolerogenic approaches
- Mechanism-focused innovations
- Novel antibody and multispecific formats
- Overcoming formulation and delivery challenges
Targeting the Gut
- Clinical and preclinical updates
- Delivery and stability strategies
- Gaps and progress in Crohn’s disease, ulcerative colitis, and IBD
- Novel therapeutic modalities and mechanism-focused strategies
- T cell modulation and engineered cell therapies to induce tolerance in the gut
Other Autoimmune Indications
- Cardiovascular and systemic autoimmunity
- Neurological autoimmunity
- Rare and emerging indications
Research Tools and Models
- Advanced translational models
- AI in drug design and optimization
- Multiomics integration
- Patient stratification and responder identification
- PK/PD modeling and simulation
Learnings from Cancer
- Checkpoint modulation
- Engineering for safety and selectivity
- Managing immunotherapy-induced autoimmunity
- Next-gen modalities crossing over
- Repurposing oncology biologics
The deadline for priority consideration is October 31, 2025.
All proposals are subject to review by session chairpersons and/or the Scientific Advisory Committee to ensure the overall quality of the conference program. Additionally, as per Cambridge Healthtech Institute’s policy, a select number of vendors and consultants who provide products and services will be offered opportunities for podium presentation slots based on a variety of Corporate Sponsorships.
Opportunities for Participation: